Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 268.42 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $630.000 thousand which beat the analyst consensus estimate of $366.667 thousand by 71.82 percent. This is a 96.42 percent decrease over sales of $17.575 million the same period last year.